Aspergillus Serology Predicts Relapse in Chronic Pulmonary Aspergillosis: Implications for Personalised Follow‐Up Strategies
Mycoses · 2026
DOI: 10.1111/myc.70156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycoses, 2026. Verfasst von Annabel Choyce und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Aspergillosis Centre, Department of Infectious Diseases, Manchester University NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Pulmonary Aspergillosis, Antibodies, Fungal, Aspergillus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Relapses occur in up to 40% of patients after prolonged courses of antifungal treatment for chronic pulmonary aspergillosis (CPA). The factors predisposing to relapse remain poorly defined.
Methods
We conducted a retrospective study of adults treated for ≥ 6 months with oral azoles for CPA. Patients who completed antifungal therapy and were deemed not to require further treatment were included. Demographic, clinical, radiological and serological data at treatment completion were collected. CPA relapse was defined as symptomatic and radiological deterioration leading to re‐initiation of antifungal therapy. Cox regression and Kaplan–Meier analyses were used to identify predictors of relapse and mortality.
Results
Among 125 patients (56% male; mean age 61 years), median treatment duration was 36 months. Thirty‐two (26%) developed relapse; relapse rate at 1 year was 16%. Aspergillus sensitisation (specific IgE > 0.35 IU/mL) and elevated Aspergillus ‐specific IgG (> 40 mg/L) at treatment completion were independently associated with relapse ( p < 0.05). No patient with IgG < 40 mg/L relapsed. Underlying lung disease (COPD or prior tuberculosis), extent of radiological involvement, or treatment duration were not significantly associated with relapse or mortality.
Conclusions
Aspergillus sensitisation and persistently elevated Aspergillus ‐specific IgG at the end of antifungal therapy were independent predictors of CPA relapse. These parameters may reflect ongoing fungal airway burden and can help identify patients requiring extended or closer post‐treatment follow‐up. Underlying comorbidities were not associated with relapse risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Aspergillosis Centre, Department of Infectious Diseases, Manchester University NHS Foundation Trust, Manchester, UK.
- Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
- Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
- Department of Infectious Diseases, Manchester University NHS Foundation Trust, Manchester, UK.
- Manchester Fungal Infection Group, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
ORCID-Profile: Chris Kosmidis
Zitieren
APA
Choyce, A., Colombo, S., Cyriac, C., Alasfour, A., Ng, W. K., Amphlett, L., & Kosmidis, C. (2026). Aspergillus Serology Predicts Relapse in Chronic Pulmonary Aspergillosis: Implications for Personalised Follow‐Up Strategies. Mycoses. https://doi.org/10.1111/myc.70156
Vancouver
Choyce A, Colombo S, Cyriac C, Alasfour A, Ng WK, Amphlett L, et al. Aspergillus Serology Predicts Relapse in Chronic Pulmonary Aspergillosis: Implications for Personalised Follow‐Up Strategies. Mycoses. 2026. doi:10.1111/myc.70156
BibTeX
@article{Choyce2026,
author = {Choyce, Annabel and Colombo, Stefano and Cyriac, Cyrin and Alasfour, Abdulrazaq and Ng, Wai Kien and Amphlett, Lauren and Kosmidis, Chris},
title = {Aspergillus Serology Predicts Relapse in Chronic Pulmonary Aspergillosis: Implications for Personalised Follow‐Up Strategies},
journal = {Mycoses},
year = {2026},
doi = {10.1111/myc.70156}
}
EUVIMED